Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes (Nasdaq: ALKS) reported positive topline results from the phase 3 REVITALYZ study of once-nightly LUMRYZ in adults with idiopathic hypersomnia. LUMRYZ met the primary ESS endpoint and key secondary PGI-C and IHSS endpoints (all p<0.0001) versus placebo, with a safety profile consistent with prior data. Alkermes plans to file an sNDA by end of 2026 but cannot market LUMRYZ for IH before March 1, 2028.
Alkermes (Nasdaq: ALKS) reported financial results for the quarter ended March 31, 2026 and provided financial expectations for full year 2026. The company will discuss results on a live conference call and webcast at 8:00 a.m. ET / 1:00 p.m. BST on May 5, 2026.
Investors can access the webcast and replay, and find the detailed earnings release and presentation, on Alkermes' investor relations website.
Alkermes (Nasdaq: ALKS) will report first quarter 2026 financial results and host a conference call and webcast on May 5, 2026 at 8:00 a.m. ET (1:00 p.m. BST). The webcast and slides will be available on the company website; a replay will be posted about two hours after the event.
Dial-in numbers are provided for U.S. and international callers; investor relations contact: Sandy Coombs, +1 781 609 6377.
Alkermes (Nasdaq: ALKS) will present new Vibrance-1 phase 2 data for alixorexton at AAN 2026 showing clinically meaningful, statistically significant improvements in wakefulness, cognition and fatigue in NT1 patients. The 92-patient trial included a six-week randomized period plus a seven-week open-label extension; >95% completed 13 weeks.
No serious treatment-emergent adverse events were reported; phase 3 Brilliance NT1 study is ongoing and alixorexton holds FDA Breakthrough Therapy designation for NT1.
Alkermes (Nasdaq: ALKS) announced publication of a 56-week post hoc analysis in The Journal of Clinical Psychiatry showing LYBALVI (olanzapine and samidorphan) was associated with sustained reductions in negative symptoms of schizophrenia over 56 weeks.
Key results: PANSS Negative Subscale LS mean change −7.6 and Marder Negative Factor −8.2 at week 56 (n=281 completers).
Alkermes (Nasdaq: ALKS) initiated the Phase 3 Brilliance Studies of alixorexton, an oral selective orexin 2 receptor agonist, in adults with narcolepsy type 1 and type 2 on April 1, 2026. The program comprises three 12-week, randomized, double-blind, placebo-controlled studies testing once-daily and split-dose regimens.
Primary endpoints measure wakefulness by mean sleep latency on the MWT; secondary endpoints include ESS, weekly cataplexy rate, patient-reported outcomes, safety, and long-term open-label follow-up eligibility.
Alkermes (Nasdaq: ALKS) launched the inaugural Alkermes Pathways APN Research Awards™, a competitive grant program open March 16, 2026 through June 1, 2026. The program offers individual research grants up to $10,000 to licensed psychiatric-mental health nurse practitioners studying schizophrenia or bipolar I disorder.
Applicants must work in clinical, academic, or community health settings and hold a doctoral degree or have a doctoral co-investigator; awards will be reviewed by an independent committee.
Alkermes (Nasdaq: ALKS) will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The live webcast will be available under the Investors tab at www.alkermes.com and will be archived for 14 days for later viewing.
The company description notes a neuroscience-focused pipeline with late-stage narcolepsy and idiopathic hypersomnia candidates and early-stage orexin 2 receptor agonists for neurological disorders.
Alkermes (Nasdaq: ALKS) reported fourth-quarter and full-year 2025 financial results and issued 2026 financial expectations on Feb 25, 2026. The company will host a conference call and webcast at 8:00 a.m. EST the same day to discuss results and outlook.
The release highlights Alkermes' commercial neuroscience portfolio and ongoing clinical programs in narcolepsy, idiopathic hypersomnia and orexin 2 receptor agonists for other neurological disorders.
Alkermes (Nasdaq: ALKS) announced a planned CEO succession: Richard Pops will retire as CEO effective July 31, 2026, and Blair Jackson will become CEO effective Aug. 1, 2026, while Pops will remain as Board chairman and advisor.
The company cites ~$1.5 billion annual revenue, the recent acquisition of Avadel and an advancing orexin agonist pipeline including an FDA Breakthrough Therapy designation for alixorexton for narcolepsy type 1.